Does Rectal Indomethacin Given for Prevention of Post-ERCP Pancreatitis Increase Bleeding After Biliary Endoscopic Sphincterotomy or Cardiovascular Mortality?

Post Hoc Analysis Using Prospective Clinical Trial Data

Árpád Patai, MD, Norbert Solymosi, PhD, and Árpád V. Patai, MD

Abstract: Rectal indomethacin has been proven to be effective for prevention of post-ERCP pancreatitis (PEP) but its impact on bleeding after biliary sphincterotomy (BABES) and cardiovascular mortality has not been extensively studied. We aimed to assess the effect of indomethacin on the rate of BABES and short-term cardiovascular mortality, particularly in patients receiving antiplatelet therapy (APT).

In this double-blind, randomized, placebo-controlled, single-center study, 100 mg indomethacin or placebo was given within 1 hour before biliary endoscopic sphincterotomy to in-patients including those who are receiving APT (acetylsalicylic acid [ASA] and/or clopidogrel). Cardiovascular mortality and BABES were observed for 30 days.

Of 576 randomized patients (289 indomethacin, 287 placebo), 87 patients used 100 mg/day ASA and 29 patients took 75 mg/day clopidogrel, among them 5 patients were on dual APT. The ASA and clopidogrel taking patients were older than patients without APT ($P < 0.001$), but these groups were similar in other parameters. BABES occurred similarly in different subgroups: indomethacin (8.0%) vs placebo (9.4%) ($P = 0.56$), ASA (10.3%) vs non-ASA (8.4%) ($P = 0.54$), clopidogrel (6.9%) vs nonclopidogrel (8.8%) ($P > 0.99$). No BABES was observed among patients on dual APT. There was no difference in cardiovascular mortality between subgroups ($P > 0.99$).

Results indicate that single dose of 100 mg indomethacin does not increase BABES rate and cardiovascular mortality. This result is independent of administering antiplatelet agents.

(Medicine 93(26):e159)

Abbreviations: APT = antiplatelet agent, APT = antiplatelet therapy, ASA = acetylsalicylic acid, BABES = bleeding after biliary endoscopic sphincterotomy, BES = biliary endoscopic sphincterotomy, ERCP = endoscopic retrograde cholangiopancreatography, Hgb = hemoglobin, INR = international normalized ratio, LMWH = low molecular weight heparin, NSAIDs = nonsteroidal anti-inflammatory drugs, PEP = post-ERCP pancreatitis.

INTRODUCTION

Rectal indomethacin has been proven to be effective for prevention of post-ERCP pancreatitis (PEP).1–5 Similar to other nonsteroidal anti-inflammatory drugs (NSAIDs), indomethacin has platelet inhibiting function and can be considered to elevate the risk of bleeding after biliary endoscopic sphincterotomy (BABES). Antiplatelet agents (APA), which are widely used in cardiovascular patients for the prevention of stent or atherothrombosis could further increase the risk of BABES. Indomethacin has been reported not only to influence the activity of acetylsalicylic acid (ASA),6 but also to elevate the risk of cardiovascular events in APA takers.6

According to European,7 American,8 and British9 clinical practice guidelines, biliary endoscopic sphincterotomy (BES) is classified as a high-risk endoscopic procedure causing hemorrhage, and the use of ASA is suggested in those receiving APAs. However the guidelines lack recommendations for those patients who take APA regularly and receive indomethacin for PEP prophylaxis, and have to undergo urgent BES. In this prospective, randomized, double blind trial, study participants undergoing BES received 100 mg indomethacin for prophylaxis of PEP within 1 hour before ERCP. The aim of this work was to study BABES and cardiovascular mortality after indomethacin and analyze its effect in APA takers’ subgroups.

METHODS

Study Design

Between December 15, 2008, and January 13, 2013, a total of 576 patients with intact papilla underwent BES at the 1st Department of Medicine and Gastroenterology, Sopron Elisabeth Teaching Hospital. All patients were included in a randomized, prospective, double blind clinical trial to study the effect of rectally administered indomethacin for BABES. ASA 100 mg or clopidogrel 75 mg, if those were indicated, were not discontinued. This study was performed in accordance with the Declaration of Helsinki and the ICH Guidelines for Good Clinical Practice. The protocol was approved by the Medical Ethics Committee of Sopron Elisabeth Teaching Hospital (17-40/2008).

Randomization and Masking

Indomethacin treatment allocation and concealment were conducted in a blinded fashion by an independent pharmacy...
staff in a separate building preparing suppositories of identical appearance that contained either 100 mg indomethacin or placebo. Block size of 20 was chosen to make sure participants were enrolled with a 1 : 1 ratio of the indomethacin group to the placebo group. Neither patients nor investigators were able to differentiate participant’s treatment group.

Study Protocol

A single dose of suppository was administered rectally within 1 hour before BES as peak concentration of indomethacin in suppository form is known to occur between 30 and 90 minutes after insertion with an elimination half-life of 2 hours.\(^{1,10}\) Each patient was observed in the hospital at least for 24 hours and heart rate, blood pressure, and blood counts were measured 24 hours after BES. Patients received at least 2000 mL IV fluids. The protocol described to break the code of indomethacin at anaphylaxis or at discretion of treating team. Platelet transfusion was available, if it was necessary.

Patients

ERCP with proposed biliary therapy was performed in unselected, consecutive in-hospital patients with naïve papilla following routine admission; history, physical examination, abdominal ultrasonography, and laboratory tests (Figure 1). Exclusion criteria included age under 18 years, pregnancy or lactation, upper gastrointestinal obstruction, history of Billroth II or Roux-en-Y anastomosis, history of allergy to indomethacin or contrast medium, serum creatinine level above 1.41 mg/dL (125 μmol/L), international normalized ratio (INR) above 1.5 (if it was necessary, vitamin K and/or fresh frozen plasma was administered to decrease INR), platelet count < 50 × 10⁹/L, the use of NSAIDs within 1 week before admission and refusal to participate in the study. Temporary holding of antiplatelet therapy (APT) was considered for any patient before ERCP. If APAs were not necessary, they were discontinued at least 7 days before ERCP. If ASA and/or clopidogrel therapy could not be safely interrupted before BES, ERCP was performed during maintained APT. Patients with sphincterotomy of the minor papilla, previous severe PEP, or papillotomy were excluded; in these cases, insertion of prophylactic pancreatic stent was performed. All patients gave written informed consent before enrollment.

ERCP

All ERCP procedures were performed by 1 endoscopy expert (AP) with standard therapeutic duodenoscope (Fuji EPX2200 processor, ED 250XT8, Fujifilm, Tokyo, Japan) in short loop position. The patients received topical pharyngeal anesthesia (1% lidocaine) and intravenous administration of midazolam (5 to 10 mg) and/or atropine (0.5 mg) and/or pethidine 50 to 100 mg for moderate sedation. Buthylscopolamine (5 to 10 mg) and/or atropine (0.5 mg) and/or pethidine 50 to 100 mg for moderate sedation, Bulthyscopolamine (Buscopen, Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany) was used as smooth muscle relaxant according to the endoscopist’s decision. Last dose of low molecular weight heparin (LMWH) was given at least 12 hours before BES and ERCP was performed at INR < 1.5. Heart rate and oxygen saturation were monitored; nasal cannula oxygen was given if necessary. Air was used for luminal insufflation during ERCP. The cannulation of common biliary duct was performed by papillotome (with double lumen, tapered nose, cutting length of 30 mm, Medwork PAPI-CF-20–35–DL, Medwork GmbH, Höchstadt/Aisch, Germany) and hydrophilic guide wire (with a diameter of 0.035-in., Jagwire, Boston Scientific Corp., Natick, MA) if necessary. Contrast medium amidotrizoate (Peritrast 600 mg/mL, Dr. Franz Köhler Chemie GmbH, Benheim, Germany) was diluted to 50% in distilled water and injected manually. Zipper cut was planned to be avoided in every BES. During our previous 6000 ERCPs, we experienced moderate and very rarely serious BABES without mortality; however, moderate and serious PEPs (among them necrotizing PEP leading to death) occurred much more frequently. For this reason, in 2007 and 2008 when we planned this trial, accepting opinion of others,\(^{11–15}\) we preferred prevention of PEP and decided to apply pure-cut current (45W) (Surgistat, Valleylab, Covidien, Boulder, CO) in all endoscopic sphincterotomies.

BABES

Cases with BABES were divided into 2 categories: immediate (intraprocedural) and delayed (postprocedural) bleeding. As in our praxis appearance of some oozing after BES is frequent with no further consequences, it was not considered as a bleeding event. Intraprocedural bleeding was diagnosed in cases in which hemostasis (electrocoagulation or injection of epinephrine) was necessary during biliary endoscopy. This procedure was indicated in 2 situations: hemorrhage was intensive according to the judgment of our expert, or bleeding did not stop 3 min after BES or the last endoscopic therapeutic maneuver. Postprocedural bleeding was defined in patients with clinical signs of bleeding or if the decrease of hemoglobin level (Hgb) was greater than 20 g/L within 24 hours but after completion of BES and subsequent upper gastrointestinal endoscopy did not show other source of bleeding. Bleeding was graded by consensus criteria\(^{16}\): mild bleeding was defined as clinical (not just endoscopic) evidence of bleeding, Hgb drop was < 30 g/L, and no transfusion was necessary; moderate bleeding was defined as Hgb drop ≥ 30 g/L or the need for transfusion was no > 4 units and angiography or surgery was not necessary; serious bleeding was defined when the need for transfusion was 5 or more units or angiographic or surgical interventions were necessary. Each patient was monitored for at least 30 days. Every discharged patient was informed about the signs of gastrointestinal hemorrhage and was asked to return if they noticed any signs of bleeding. Patients were checked within 6 weeks after BES and were asked about symptoms of hemorrhage. In case of the death of a patient, autopsy was planned in every case.

Statistical Analysis

This work is a subsequent analysis of our PEP study.\(^4\) In this work patients without BES were excluded, but the current cohort included 63 patients with acute biliary pancreatitis originally excluded from the PEP study (Figure 1). For the univariate analysis of outcome (PEP) two-tailed Fisher exact test was used.\(^{17}\) Student’s t-test was used to compare groups with continuous variables. Multivariate analysis was performed by logistic regression. A P value of < 0.05 was considered significant. All statistical analyses were performed by using the R-environment.\(^{18}\)

RESULTS

Patients’ Disposition and Baseline Characteristics

A total of 637 patients with proposed biliary endoscopic therapy were initially randomized into this study (Figure 1). Sixty-one patients were excluded after allocation: in 20 patients, the major papilla could not be reached because of upper gastrointestinal obstruction and its intradiverticular position
in 10 patients the cannulation of bile duct was unsuccessful. In 16 patients, endoscopic therapy was not necessary; therefore, BES was not performed. Fourteen patients received pancreatic stent according to protocol. An additional patient was excluded from the placebo group because of inability to retain the suppository in the rectum. Finally, 576 patients were analyzed. Zipper cut could be avoided in all BES cases.

In our earlier study indomethacin decreased PEP rate from 13.8% to 6.7% \((P < 0.007)\). Two-hundred eighty-nine patients in the indomethacin group and 287 patients in the placebo group did not differ from each other in mean age, age \(< 50\) years, gender, average platelet count, papillary stenosis, and endoscopic procedures (frequency of precut, lithotripsy, biliary stent implantation), only cholangitis occurred more frequently in the indomethacin group \((P < 0.01)\) (Table 1, Supplementary Table 1, http://links.lww.com/MD/A76). In our trial, 87 patients used 100 mg/day of ASA and 29 patients regularly received 75 mg/day of clopidogrel, 5 patients had dual APT. Patients on ASA and clopidogrel were significantly older \((P < 0.001)\) than those not taking APAs, and among patients not taking ASA there were significantly more females \((P < 0.05)\). Patients on APT did not differ from each other in platelet count and endoscopic procedures (Table 1).

**TABLE 1.** Antiplatelet Therapy, Demographical, and Clinical Characteristics of Study Patients

|                        | Indomethacin | No Indomethacin | \(P\) Value | ASA | No ASA | \(P\) Value | Clopidogrel | No Clopidogrel | \(P\) Value |
|------------------------|--------------|-----------------|-------------|-----|--------|-------------|-------------|----------------|-------------|
| Number of patients     | 289          | 287             | 0.21        | 87  | 489    | <0.001      | 29          | 547            | <0.001      |
| Mean age, year ± SD    | 65.8 ± 16.3  | 64.1 ± 16.9     | 0.21        | 71.0 ± 11.1 | 63.9 ± 17.2 | <0.001      | 72.6 ± 7.0 | 64.6 ± 16.9    | <0.001      |
| Age ≤ 50 years (%)     | 20.1         | 22.7            | 0.48        | 4.6 | 24.3   | <0.001      | 0           | 22.5           | <0.01       |
| Sex, female (%)        | 67.8         | 65.9            | 0.66        | 57.5 | 68.5   | <0.05       | 69.0        | 66.7           | <0.001      |
| Papillary stenosis (%) | 13.5         | 15.0            | 0.64        | 16.1 | 13.9   | 0.62        | 20.7        | 13.9           | 0.28        |
| Cholangitis (%)        | 41.9         | 31.4            | <0.01       | 33.3 | 37.2   | 0.55        | 37.9        | 36.6           | <0.001      |
| Platelet count, \(10^9/\text{L} \pm \text{SD}\) | 241.3 ± 96.6 | 246.3 ± 87.6    | 0.51        | 232.3 ± 115.4 | 245.8 ± 87.4 | 0.30        | 231.3 ± 67.1 | 244.4 ± 93.3  | 0.32        |
| Precut (%)             | 16.6         | 16.0            | 0.91        | 20.7 | 15.5   | 0.27        | 17.2        | 16.3           | 0.80        |
| Lithotripsy (%)        | 5.2          | 5.6             | 0.86        | 2.3  | 5.9    | 0.21        | 3.5         | 5.5            | <0.001      |
| Biliary stent implantation (%) | 29.8 | 23.3         | 0.09        | 19.5 | 27.8   | 0.12        | 27.6        | 26.5           | 0.83        |

ASA = acetylsalicylic acid, SD = standard deviation.
complications. When intra procedural bleeding occurred, we immediately switched from pure-cutting current to coagulation in 13 cases, and the bleeding stopped. In another 4 patients, coagulation was applied after 3 minutes. In 1 of these 4 cases, coagulation was insufficient, therefore, 2 mL diluted epinephrine was injected. All the bleedings were stopped at the end of ERCP. Postprocedural bleeding was detected from 3 hours to 19 days after BES (in 30 out of 36 patients with postprocedural bleeding BABES was observed in the first 24 hours), but endoscopic therapy was only necessary in 5 cases. Injection of diluted epinephrine was effective in 4 patients, in 1 patient heat probe unit was applied after injection of diluted epinephrine. Two of these patients were on clopidogrel: 1 patient used ASA, and 2 patients received indomethacin before BES. No patient required surgery; however, 1 patient had to receive 2 units of red blood cells, and she did not take any APAs.

On 30-day follow-up, we did not detect mortality related to BABES (Supplementary Table 3, http://links.lww.com/MD/A76). One patient died from PEP (0.2%), she did not take indomethacin, ASA, or clopidogrel. Nine patients (1.6%) died due to causes independent of the procedure; in the indomethacin group 1 ASA user died due to cardiac failure, 1 patient died due to complications of cholecystectomy, and 1 patient died due to malignant disease, whereas in the placebo group 1 patient died due to myocardial infarction (she did not take ASA or clopidogrel) and 3 patients died due to malignant disease. One patient in the indomethacin and 1 patient in the placebo group died due to severe necrotizing biliary pancreatitis despite successful BES and biliary stone extraction. All deceased patients underwent autopsy, no signs of bleeding was detected. Cardiovascular mortality in groups of different APAs users did not differ from each other.

Patients with and without bleeding did not differ from each other in age, sex, endoscopic therapy, and APA use; however, patients with BABES had lower platelet count ($P = 0.01$) (Table 3). Multivariate analysis did not show any risk for bleeding regarding demographical data, endoscopic procedures, and different APAs (Table 4). BABES was graded according to consensus criteria.16 Forty-three patients (86%) had mild bleeding and 7 patients (14%) had moderate bleeding. We did not detect any serious bleeding. Grade of hemorrhage did not differ from each other according to different APAs. We investigated the interaction of indomethacin and ASA (Table 5). There was no significant difference concerning BABES.

**DISCUSSION**

According to our knowledge, this is the first prospective randomized, double blind trial for analyzing the occurrence of BABES in patients using single dose of indomethacin and additional ASA ($n = 87$) and clopidogrel ($n = 29$). Our results indicate that there is no difference in the risk of BABES with regard to the prior use of indomethacin and holding of ASA or clopidogrel even though patients taking ASA and clopidogrel in our cohort were significantly older than those without APT. Guidelines suggest holding the administration of clopidogrel before BES and continuing ASA only in patients treated by dual APT, if it is not contraindicated.7–9 It has been reported that ASA and NSAIDs do not increase the risk for bleeding after colonic polypectomy,19 a procedure with similar bleeding risk to BES.19 Publications for BABES in patients using ASA or NSAIDs are controversial. According to the only prospective study related to this subject, BABES was independent from the use of ASA and NSAIDs within 3 days preceding endoscopic intervention.20 In a retrospective case-control study, BABES was significantly more frequent regardless whether patients

### TABLE 2. BABES in Patients Treated With Indomethacin, ASA, and Clopidogrel

|                | Indomethacin, $n = 289$ | No Indomethacin, $n = 287$ | $P$ Value | ASA, $n = 87$ | No ASA, $n = 489$ | $P$ Value | Clopidogrel, $n = 29$ | No Clopidogrel, $n = 547$ | $P$ Value |
|----------------|------------------------|-----------------------------|-----------|--------------|-----------------|-----------|----------------------|---------------------------|-----------|
| Overall postsphincterotomy bleeding, n (%) | 23 (8.0) | 27 (9.4) | 0.56 | 9 (10.3) | 41 (8.4) | 0.54 | 2 (6.9) | 48 (8.8) | <0.999 |
| Intraprocedural, n (%) | 10 (3.5) | 7 (2.4) | 0.62 | 4 (4.6) | 13 (2.7) | 0.31 | 1 (3.5) | 16 (2.9) | 0.59 |
| Postprocedural, n (%) | 14 (4.8) | 22 (7.7) | 0.17 | 5 (5.8) | 31 (6.3) | <0.999 | 1 (3.5) | 35 (6.4) | <0.999 |

ASA = acetylsalicylic acid, BABES = bleeding after biliary sphincterotomy.

### TABLE 3. Comparison of Patients With and Without Bleeding

|                        | Patients With Bleeding | Patients Without Bleeding | $P$ Value |
|------------------------|------------------------|---------------------------|-----------|
| Mean age, years ± SD   | 66.7 ± 16.1            | 64.8 ± 16.7               | 0.43      |
| Age ≤ 50 years (%)     | 16                     | 21.9                      | 0.37      |
| Sex, female (%)        | 72                     | 66.4                      | 0.53      |
| Platelet count 10^3/µL ± SD | 216.3 ± 79.3            | 246.4 ± 92.9               | 0.01      |
| Precut (%)             | 16                     | 16.4                      | <0.999    |
| Lithotripsy (%)        | 6                      | 5.3                       | 0.74      |
| Biliary stent implantation (%) | 26                      | 26.6                      | <0.999    |
| Indomethacin (%)       | 46                     | 50.6                      | 0.56      |
| ASA (%)                | 18                     | 14.8                      | 0.54      |
| Clopidogrel (%)        | 4                      | 5.1                       | <0.999    |

ASA = acetylsalicylic acid, SD = standard deviation.

### TABLE 4. Multivariate Analysis Identifying Risk Factors for BABES

|                        | Odds Ratio | 95% CI | $P$ Value |
|------------------------|------------|--------|-----------|
| Age > 50 years (%)     | 1.52       | 0.67–3.42 | 0.32     |
| Sex, female (%)        | 1.36       | 0.71–2.60 | 0.36     |
| Precut (%)             | 0.98       | 0.43–2.17 | 0.95     |
| Lithotripsy (%)        | 1.06       | 0.30–3.70 | 0.93     |
| Biliary stent implantation (%) | 0.94     | 0.48–1.86 | 0.86     |
| Indomethacin (%)       | 0.83       | 0.46–1.49 | 0.53     |
| ASA (%)                | 1.20       | 0.55–2.64 | 0.64     |
| Clopidogrel (%)        | 0.72       | 0.16–3.14 | 0.66     |

ASA = acetylsalicylic acid, BABES = bleeding after biliary sphincterotomy, CI = confidence interval.
stopped taking ASA 1 week before BES or remained on ASA throughout BES.21 However, this result seems to be controversial as evidence indicates that platelet aggregation is normalized 7 days after stopping ASA treatment.22 In addition, this study was criticized by Hussain and coworkers18 for the definition of BABES and statistical analysis. In Hussain’s retrospective case-control study, ASA and NSAID did not increase risk for BABES.23

The incidence of BABES can range widely from 1.1% to 48% depending on the rate of therapeutic ERCP and on the definition of BABES.16,20,24–29 As far as we are concerned, our definition is able to register all bleeding events (excluding spontaneous resolution) and, therefore, we can obtain exact information of incidence of BABES to compare the effect of APAs. Frequency of BABES observed in our study was 8.7%, corroborating the findings of a study, in which the rate of BABES was 10.4% if epinephrine injection was applied when bleeding did not stop 2 minutes following BES.30 According to literature recommended, waiting time for spontaneous stopping of hemorrhage before initializing endoscopic hemostasis varies between 3 minutes31 and 5 minutes32. In our study, this time was defined as 3 minute. Mortality of BABES ranges from 0.3%16 to 3.54%,28 although in our cohort we detected no mortality due to BABES in our study, this time was of hemorrhage before initializing endoscopic hemostasis varies literature recommended, waiting time for spontaneous stopping defined as 3 minute. Mortality of BABES ranges from 0.3%16 to 3.54%,28 whereas 6.3% postprocedural bleeding, which is similar to 10.3 and 4.2% in earlier studies.30,31

In conclusion, results of our prospective study indicate that single dose of indomethacin does not increase short-term cardiovascular mortality and this result is similar in APA takers and non-APA takers. Moreover, we provide evidence that the use of indomethacin for the prevention of PEP has no impact on the rates of intraprocedural and postprocedural bleeding following biliary sphincterotomy.

ACKNOWLEDGMENT

The authors thank Dr György Baffy (Department of Medicine, Veterans Affairs Boston Healthcare System and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA) for critical reading of the manuscript, Piroska Pázmány for linguistic overview and Dr Judit Kardos (Hospital Pharmacy, Sopron Elizabeth Teaching Hospital) for her help in preparing the suppositories and her assistance in the randomization.

REFERENCES

1. Sotoudehmanesh R, Khatibian M, Kolahdooz S, et al. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007;102:978–983.

2. Montaño Loza A, Rodríguez Homeli X, García Correa JE, et al. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes [in Spanish]. Rev Esp Enferm Dig. 2007;99:330–336.

3. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012;366:1414–1422.

4. Patai A, Solymosi N, Patai AV. Effect of rectal indomethacin for preventing post-ERCP pancreatitis depends on difficulties of cannulation: results from a randomized study with sequential biliary intubation. J Clin Gastro. 2014 June 25 Epub ahead of print, DOI: 10.1097/MCG.0000000000000168.

© 2014 Lippincott Williams & Wilkins

Table 5. Post-Sphincterotomy Bleeding in ASA and Indomethacin Users

| No ASA and No Indomethacin (n = 242) | ASA and Indomethacin (n = 42) | P value | No ASA and No Indomethacin (n = 45) | P Value | No ASA and Indomethacin (n = 247) | P Value |
|-------------------------------------|--------------------------------|---------|-------------------------------------|---------|-------------------------------------|---------|
| Overall postsphincterotomy bleeding, n (%) | 20 (8.3) | 2 (4.8) | 0.75 | 7 (15.6) | 0.16 | 21 (8.5) | <0.001 |
| Immediate (intraprocedural), n (%) | 5 (2.1) | 2 (4.8) | 0.28 | 2 (4.4) | 0.3 | 8 (3.2) | 0.58 |
| Delayed (postprocedural), n (%) | 17 (7.0) | 0 (0) | 0.09 | 5 (11.1) | 0.36 | 14 (5.7) | 0.58 |

ASA = acetylsalicylic acid.

Three patients had both intraprocedural and postprocedural bleeding. *P value as compared with no ASA and no indomethacin taking patients.
5. Gladding PA, Webster MWI, Farrel HB, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. *Am J Cardiol.* 2008;101:1060–1063.

6. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. *JAMA.* 2006;296:1633–1644.

7. Boustie`re C, Veitch A, Vanbiervliet G, et al. Endoscopy and antiplatelet agents. European Society of Gastroenterology (ESGE) guideline. *Endoscopy.* 2011;43:445–458.

8. Anderson MA, Ben-Menachem T, Gan SI, et al., ASGE Standards of Practice Committee. Management of antithrombotic agents for endoscopic procedures. *Gastrointest Endosc.* 2009;70:1060–1070.

9. Veitch AM, Baglin TP, Gershlick AH, et al. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. *Gut.* 2008;57:1322–1329.

10. Murray B, Carter R, Imrie C, et al. Diclofenac may reduce the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. *Gastroenterology.* 2003;124:1786–1791.

11. Elta GH, Barnett JL, Wille RT, et al. Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current. *Gastrointest Endosc.* 1998;47:149–153.

12. Pasricha P. Current news about sphincterotomy-induced pancreatitis: does electrocautery setting make a difference? *Gastroenterology.* 1998;115:1024–1025.

13. Gorelick A, Cannon M, Barnett J, et al. First cut, then blend: an electrosurgical technique affecting bleeding at sphincterotomy. *Endoscopy.* 2001;33:976–980.

14. Stefanidis G, Karamanolis G, Viazis N, et al. A comparative study of postendoscopic sphincterotomy complications with various types of electrosurgical current in patients with choledocholithiasis. *Gastrointest Endosc.* 2003;57:192–197.

15. Ferreira LE, Baron TH. Post-sphincterotomy bleeding: who, what, when, and how. *Am J Gastroenterol.* 2007;102:2850–2858.

16. Cotton PB, Lehman G, Veness JU, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointest Endosc.* 1991;37:383–392.

17. Agresti A. Categorical data analysis. New York: Wiley; 2002: pp. 91–101.

18. R Core Team R. A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna; 2012. http://www.R-project.org. [Accessed September 19 2013]

19. Manocha D, Singh M, Mehta N, et al. Bleeding risk after invasive procedures in aspirin/NSAID users: polypectomy study in veterans. *Am J Med.* 2012;125:1222–1227.

20. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. *N Engl J Med.* 1996;335:909–918.

21. Hui CK, Lai KC, Yuen MF, et al. Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding? *Aliment Pharmacol Ther.* 2002;16:929–936.

22. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. *J Clin Invest.* 1983;71:676–688.

23. Hussain N, Alsulaiman R, Burtin P, et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. *Aliment Pharmacol Ther.* 2007;25:579–584.

24. Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. *Gastrointest Endosc.* 2009;70:800–808.

25. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. *Gastrointest Endosc.* 1998;48:1–10.

26. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. *Am J Gastroenterol.* 2001;96:417–423.

27. ASGE Standards of Practice Committee. Complications of ERCP. *Gastrointest Endosc.* 2012;75:67–73.

28. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *Am J Gastroenterol.* 2007;102:1781–1788.

29. Mellinger JD, Ponsky JL. Bleeding after endoscopic sphincterotomy as an underestimated entity. *Surg Gynecol Obstet.* 1991;172:465–469.

30. Kim HJ, Kim MH, Kim DI, et al. Endoscopic hemostasis in sphincterotomy-induced hemorrhage: its efficacy and safety. *Endoscopy.* 1999;31:431–436.

31. Leung JW, Chan FK, Sung JJ, et al. Endoscopic sphincterotomy-induced hemorrhage. A study of risk factors and the role of epinephrine injection. *Gastrointest Endosc.* 1995;42:550–554.

32. Wilcox CM, Canakis J, Mönkemüller KE, et al. Patterns of bleeding, the subsequent risk of bleeding and the role of epinephrine injection. *Am J Gastroenterol.* 2004;99:244–248.

33. Williams EJ, Taylor S, Fairclough P, et al. Risk factors for complication following ERCP: results of a large-scale, prospective multicenter study. *Endoscopy.* 2007;39:793–801.

34. Manes G, Di Diorio P, Repici A, et al. An analysis of the factors associated with development of complications in patients undergoing precut sphincterotomy: a prospective controlled, randomized, multicenter study. *Am J Gastroenterol.* 2009;104:2412–2417.

35. Samie AA, Stumpf M, Sun R, et al. Biliary-pancreatic endoscopic and surgical procedures in patients under dual antiplatelet therapy: a single-center study. *Clin Endosc.* 2013;46:395–398.

36. Rey JF, Beilenhoff U, Neumann CS, et al. European Society of Gastrointestinal Endoscopy (ESGE) guideline: the use of electro-surgical units. *Endoscopy.* 2010;42:764–771.

37. Verma D, Kapadia A, Adler DG. Pure versus mixed electrosurgical current for endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes. *Gastrointest Endosc.* 2007;66:283–290.